The asian subsidiary, Endomatrix Asia, will offer direct access to a consumer base that has demonstrated openness to non-pharmaceutical health regimens.
The company aims to promote its cardiovascular health regime in the Asian community and to make Endomatrix Asia, 'a productive member' of the Singapore business community.
Scott Foster, vice president and managing director of Endomatrix Asia explained: "Working with Singapore's Economic Development Board will help us move more quickly to capitalize on the traditional non-pharmaceutical health regimens."
Endomatrix's expansion into the asian market is part of a long-term plan to deliver its products to a global audience through both nutraceutical and pharmaceutical products. The aim is to turn the company into a worldwide name, said the firm.
Dabney Oliver, Loomis Group press officer for Endomatrix, added: "We have seen great success in Europe thus far and we are currently launching in Australasia."
"The US market is multi-tiered as we are distributing to cardiologists, consumers and alternative medicine practitioners. In the US we have received strong interest from research partners and educational institutions ready to help us take the research to the next stage."
The decision to expand Endomatrix into an international corporation comes after Endomatrix announced the closure of its $3.5 million share financing in December 2003.
The money from this round of funding allowed Endomatrix to globally launch Provasca, the first product based on its Endothelial Dysfunction Therapy (EDT) platform and will allow the company to fund further clinical studies.
However, an expected launch of Provasca, particularly in the Asian market will be dependent on sales in the American sector.
"While the Asia Pacific market has already shown great enthusiasm for the research and potential benefits of Provasca, our primary market is the US," said Oliver.
The supplement Provasca is a patented blend of natural compounds including green seaweed powder extract (leaf) and L-Arginine (as l-Arginine hydrochloride) which claims to focus on the root cause of disease rather than the symptoms.
Provasca's ability to positively effect key markers of cardiovascular health was demonstrated in a proof-of-concept study conducted in the fall last year by Harrison Clinical Research of Munich, Germany.
During the study, Provasca showed noticeable positive effect among healthy, non-symptomatic subjects. This included the reduction of high sensitivity C-reactive protein (hs-CRP) levels by 43 per cent, a reduction of blood pressure by an average of 10 mmHg, an increase in HDL (good cholesterol) levels by 7 per cent and a reduction of triglyceride levels by 17 per cent.
Provasca is available as a one-month supply (60 capsules) at the recommended dosage of two-capsules per day. The supplement is delivered using Licaps capsules from the Capsugel division of Pfizer.